3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
3
Observational
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
16
Carcinoma, Hepatocellular
11
Stomach Neoplasms
6
Neoplasms
5
Colorectal Neoplasms
3
Triple Negative Breast Neoplasms
2
Small Cell Lung Carcinoma
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Myositis
2
Lung Neoplasms
2
Cholangiocarcinoma
2
Vascular Complications
1
Sjogren's Syndrome
1
Scleroderma, Systemic
1
Sarcopenia
1
Recurrence
1
Rectal Neoplasms
1
Plaque, Atherosclerotic
1
Pathologic Complete Response
1
Oropharyngeal Neoplasms
1
Neoplasm Metastasis
1
Mouth Neoplasms
1
Metastatic Colorectal Adenocarcinoma
1
Melanoma
1
Lupus Erythematosus, Systemic
1
Lung Diseases, Interstitial
1
Liver Neoplasms
1
Influenza, Human
1
Immune-Related Adverse Events
1
Hypersensitivity
1
Interventions
Hepatectomy
10
Blood Specimen Collection
9
Sorafenib
7
Polymerase Chain Reaction
4
Biopsy
4
regorafenib
3
Mass Spectrometry
3
Liver Transplantation
3
Immunohistochemistry
3
Chemoembolization, Therapeutic
3
Walking Speed
2
Surveys and Questionnaires
2
Psychiatric Rehabilitation
2
Magnetic Resonance Imaging
2
Gene Expression Profiling
2
Bevacizumab
2
trastuzumab deruxtecan
1
taxane
1
spartalizumab
1
sintilimab
1
lenvatinib
1
gadolinium ethoxybenzyl DTPA
1
donafenib
1
carmofur
1
camrelizumab
1
cabozantinib
1
atezolizumab
1
apatinib
1
anlotinib
1
Yttrium-90
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Observational
×
Liver Neoplasms
×
Immune Checkpoint Inhibitors
×
Clear all
NCT05713994
2025-03-25
CCGLC-001
Tongji Hospital
Recruiting
300 enrolled